Eli Lilly...announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating the efficacy and safety of retatrutide...in adults with type 2 diabetes and obesity or overweight (PRNewswire) - Sep 29, 2026 - "Results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD)....Participants taking retatrutide 4 mg, 9 mg, and 12 mg lost an average of 29.8 lbs (12.7%), 45.4 lbs (19.1%), and 49.6 lbs (20.8%), respectively. Among participants with a baseline BMI of 35 or higher, those taking retatrutide 12 mg lost an average of 60.8 lbs (23.4%). By the end of the study, 59.5% of participants taking retatrutide 12 mg no longer met the BMI criteria for obesity. Beyond substantially reducing weight, retatrutide also helped participants better control their A1C. Participants taking retatrutide 9 mg and 12 mg reduced their A1C by an average of 1.6% and 1.5%, respectively, while those taking 4 mg reduced their A1C by an average of 1.4%.....Lilly plans to submit a Biologics License Application (BLA) in Q1 2027 to the U.S. Food and Drug Administration."
FDA filing • P3 data • Obesity • Type 2 Diabetes Mellitus
|